YH-25724

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameYH-25724
Drug Alias NameBI-3006337YH-25724
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsFibroblast growth factor 21 agonists
TargetsGlucagon-like peptide 1 receptorFibroblast growth factor 21
Therapy Area/IndicationsObesityMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesYuhan Corp
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Inactive CompaniesN/A
Active IndicationsObesityMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A